Loading…
Evaluation of the Human T‐Cell Leukemia Virus Type I Seropositivity of Blood Donors by the Particle Agglutination Inhibition Test
In the HTLV‐I seroscreening of blood donor sera by gelatin particle agglutination (PA), more than 50% (55.6%) of the PA‐positive sera were negative by immunofluorescence assay (IF). However, when donors were divided into age groups, there were increasing numbers of IF‐positive/PA‐positive donors wit...
Saved in:
Published in: | Cancer science 1989-09, Vol.80 (9), p.833-839 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c5933-1ebf9c5baf6162366ef26f756c6c6fab0aa5fdb4f74c6599b97e185ce0723d623 |
---|---|
cites | cdi_FETCH-LOGICAL-c5933-1ebf9c5baf6162366ef26f756c6c6fab0aa5fdb4f74c6599b97e185ce0723d623 |
container_end_page | 839 |
container_issue | 9 |
container_start_page | 833 |
container_title | Cancer science |
container_volume | 80 |
creator | Kwon, Kil‐Won Ikeda, Hisami Yano, Misako Sekiguchi, Sadayoshi |
description | In the HTLV‐I seroscreening of blood donor sera by gelatin particle agglutination (PA), more than 50% (55.6%) of the PA‐positive sera were negative by immunofluorescence assay (IF). However, when donors were divided into age groups, there were increasing numbers of IF‐positive/PA‐positive donors with age. Among the PA‐positive donors in the 50–64 age group, 65.9% were IF‐positive compared to 16.0% in the 16–19 age group. The serological specificities of the IF‐negative/ PA‐positive specimens were tested by using a newly developed PA inhibition (PAD test. The HTLV‐I specificity of the PAI test was confirmed by the observation that agglutinations with anti‐HTLV‐I p19 and gp21 monoclonal antibodies as well as IF‐positive sera were specifically inhibited with HTLV‐I preparations or HTLV‐I‐positive cell extracts and not with HTLV‐I‐negative cell extracts. Sixty of the 104 specimens collected randomly from the IF‐negative/PA‐positive donors were PAI‐positive. The majority (80%) of such PAI‐positive sera showed more than two bands of HTLV‐I gag‐encoded polypeptide, p19, p24, p2S and p53 on Western blotting. Some of the PAI‐positive sera were also positive by enzyme immunoassay. These results indicate that at least some of the IF‐negative/ PA‐positive donors possess HTLV‐I‐specific antibody and may be potential HTLV‐I carriers who will become IF‐positive at a later age |
doi_str_mv | 10.1111/j.1349-7006.1989.tb01723.x |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5917853</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2400010414</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5933-1ebf9c5baf6162366ef26f756c6c6fab0aa5fdb4f74c6599b97e185ce0723d623</originalsourceid><addsrcrecordid>eNqVUs2O0zAYtBBoKYVHQLIAcUuw49ipOSCVbmErVQKJwtVyXLt1SeNiJ93NDYkX4Bl5EpxtVH4uCPtgSzPf-PN8A8ATjFIc14tdiknOkwIhlmI-4WlTIlxkJL25A0Zn6C4YIY5RQhFF98GDEHYoshDLLsBFRjEhCI3At_lRVq1srKuhM7DZanjV7mUNVz--fp_pqoJL3X7WeyvhJ-vbAFfdQcMF_KC9O7hgG3u0TdeXvq6cW8NLVzsfYNndSr2XvrGq0nC62VRtY-vTQ4t6a0t7e13p0DwE94ysgn40nGPw8c18NbtKlu_eLmbTZaIoJyTBujRc0VIahllGGNMmY6agTMVtZImkpGZd5qbIFaOcl7zQeEKVRtGadawYg1cn3UNb7vVa6brxshIHb_fSd8JJK_5EarsVG3cUlONiQkkUeD4IePeljZ2LvQ0qmiRr7dogCk44Iwz_k4gpZTmKvxqDp38Rd671dXRBZDmK80I5ziPr5YmlvAvBa3PuGSPRJ0LsRD920Y9d9IkQQyLETSx-_Puvz6VDBCL-bMBlULIyXtbKhjONFSRDWfHLvGtb6e4_GhCz6XxCCPkJMCrVlw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2400010414</pqid></control><display><type>article</type><title>Evaluation of the Human T‐Cell Leukemia Virus Type I Seropositivity of Blood Donors by the Particle Agglutination Inhibition Test</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Kwon, Kil‐Won ; Ikeda, Hisami ; Yano, Misako ; Sekiguchi, Sadayoshi</creator><creatorcontrib>Kwon, Kil‐Won ; Ikeda, Hisami ; Yano, Misako ; Sekiguchi, Sadayoshi</creatorcontrib><description>In the HTLV‐I seroscreening of blood donor sera by gelatin particle agglutination (PA), more than 50% (55.6%) of the PA‐positive sera were negative by immunofluorescence assay (IF). However, when donors were divided into age groups, there were increasing numbers of IF‐positive/PA‐positive donors with age. Among the PA‐positive donors in the 50–64 age group, 65.9% were IF‐positive compared to 16.0% in the 16–19 age group. The serological specificities of the IF‐negative/ PA‐positive specimens were tested by using a newly developed PA inhibition (PAD test. The HTLV‐I specificity of the PAI test was confirmed by the observation that agglutinations with anti‐HTLV‐I p19 and gp21 monoclonal antibodies as well as IF‐positive sera were specifically inhibited with HTLV‐I preparations or HTLV‐I‐positive cell extracts and not with HTLV‐I‐negative cell extracts. Sixty of the 104 specimens collected randomly from the IF‐negative/PA‐positive donors were PAI‐positive. The majority (80%) of such PAI‐positive sera showed more than two bands of HTLV‐I gag‐encoded polypeptide, p19, p24, p2S and p53 on Western blotting. Some of the PAI‐positive sera were also positive by enzyme immunoassay. These results indicate that at least some of the IF‐negative/ PA‐positive donors possess HTLV‐I‐specific antibody and may be potential HTLV‐I carriers who will become IF‐positive at a later age</description><identifier>ISSN: 0910-5050</identifier><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><identifier>EISSN: 1876-4673</identifier><identifier>DOI: 10.1111/j.1349-7006.1989.tb01723.x</identifier><identifier>PMID: 2513300</identifier><identifier>CODEN: GANNA2</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Age ; Age Factors ; Agglutination ; Agglutination Tests ; AIDS/HIV ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antigens, Viral - analysis ; Biological and medical sciences ; Blood donor ; Blood Donors ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; Carrier State - microbiology ; Enzyme immunoassay ; Fluorescent Antibody Technique ; Gag protein ; Gelatin ; HTLV-I Infections - microbiology ; HTLV‐I seroscreening ; Humans ; Immunoenzyme Techniques ; Immunofluorescence ; Medical sciences ; Middle Aged ; Monoclonal antibodies ; p53 Protein ; PAI ; PA‐positive/IF‐negative ; Serologic Tests ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Western blotting</subject><ispartof>Cancer science, 1989-09, Vol.80 (9), p.833-839</ispartof><rights>1990 INIST-CNRS</rights><rights>Copyright John Wiley & Sons, Inc. Sep 1989</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5933-1ebf9c5baf6162366ef26f756c6c6fab0aa5fdb4f74c6599b97e185ce0723d623</citedby><cites>FETCH-LOGICAL-c5933-1ebf9c5baf6162366ef26f756c6c6fab0aa5fdb4f74c6599b97e185ce0723d623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2400010414/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2400010414?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25728,27898,27899,36986,44563,53763,53765,75093</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6732027$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2513300$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kwon, Kil‐Won</creatorcontrib><creatorcontrib>Ikeda, Hisami</creatorcontrib><creatorcontrib>Yano, Misako</creatorcontrib><creatorcontrib>Sekiguchi, Sadayoshi</creatorcontrib><title>Evaluation of the Human T‐Cell Leukemia Virus Type I Seropositivity of Blood Donors by the Particle Agglutination Inhibition Test</title><title>Cancer science</title><addtitle>Jpn J Cancer Res</addtitle><description>In the HTLV‐I seroscreening of blood donor sera by gelatin particle agglutination (PA), more than 50% (55.6%) of the PA‐positive sera were negative by immunofluorescence assay (IF). However, when donors were divided into age groups, there were increasing numbers of IF‐positive/PA‐positive donors with age. Among the PA‐positive donors in the 50–64 age group, 65.9% were IF‐positive compared to 16.0% in the 16–19 age group. The serological specificities of the IF‐negative/ PA‐positive specimens were tested by using a newly developed PA inhibition (PAD test. The HTLV‐I specificity of the PAI test was confirmed by the observation that agglutinations with anti‐HTLV‐I p19 and gp21 monoclonal antibodies as well as IF‐positive sera were specifically inhibited with HTLV‐I preparations or HTLV‐I‐positive cell extracts and not with HTLV‐I‐negative cell extracts. Sixty of the 104 specimens collected randomly from the IF‐negative/PA‐positive donors were PAI‐positive. The majority (80%) of such PAI‐positive sera showed more than two bands of HTLV‐I gag‐encoded polypeptide, p19, p24, p2S and p53 on Western blotting. Some of the PAI‐positive sera were also positive by enzyme immunoassay. These results indicate that at least some of the IF‐negative/ PA‐positive donors possess HTLV‐I‐specific antibody and may be potential HTLV‐I carriers who will become IF‐positive at a later age</description><subject>Adolescent</subject><subject>Age</subject><subject>Age Factors</subject><subject>Agglutination</subject><subject>Agglutination Tests</subject><subject>AIDS/HIV</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Antigens, Viral - analysis</subject><subject>Biological and medical sciences</subject><subject>Blood donor</subject><subject>Blood Donors</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>Carrier State - microbiology</subject><subject>Enzyme immunoassay</subject><subject>Fluorescent Antibody Technique</subject><subject>Gag protein</subject><subject>Gelatin</subject><subject>HTLV-I Infections - microbiology</subject><subject>HTLV‐I seroscreening</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Immunofluorescence</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>p53 Protein</subject><subject>PAI</subject><subject>PA‐positive/IF‐negative</subject><subject>Serologic Tests</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Western blotting</subject><issn>0910-5050</issn><issn>1347-9032</issn><issn>1349-7006</issn><issn>1876-4673</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqVUs2O0zAYtBBoKYVHQLIAcUuw49ipOSCVbmErVQKJwtVyXLt1SeNiJ93NDYkX4Bl5EpxtVH4uCPtgSzPf-PN8A8ATjFIc14tdiknOkwIhlmI-4WlTIlxkJL25A0Zn6C4YIY5RQhFF98GDEHYoshDLLsBFRjEhCI3At_lRVq1srKuhM7DZanjV7mUNVz--fp_pqoJL3X7WeyvhJ-vbAFfdQcMF_KC9O7hgG3u0TdeXvq6cW8NLVzsfYNndSr2XvrGq0nC62VRtY-vTQ4t6a0t7e13p0DwE94ysgn40nGPw8c18NbtKlu_eLmbTZaIoJyTBujRc0VIahllGGNMmY6agTMVtZImkpGZd5qbIFaOcl7zQeEKVRtGadawYg1cn3UNb7vVa6brxshIHb_fSd8JJK_5EarsVG3cUlONiQkkUeD4IePeljZ2LvQ0qmiRr7dogCk44Iwz_k4gpZTmKvxqDp38Rd671dXRBZDmK80I5ziPr5YmlvAvBa3PuGSPRJ0LsRD920Y9d9IkQQyLETSx-_Puvz6VDBCL-bMBlULIyXtbKhjONFSRDWfHLvGtb6e4_GhCz6XxCCPkJMCrVlw</recordid><startdate>198909</startdate><enddate>198909</enddate><creator>Kwon, Kil‐Won</creator><creator>Ikeda, Hisami</creator><creator>Yano, Misako</creator><creator>Sekiguchi, Sadayoshi</creator><general>Blackwell Publishing Ltd</general><general>Japanese Cancer Association</general><general>John Wiley & Sons, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>198909</creationdate><title>Evaluation of the Human T‐Cell Leukemia Virus Type I Seropositivity of Blood Donors by the Particle Agglutination Inhibition Test</title><author>Kwon, Kil‐Won ; Ikeda, Hisami ; Yano, Misako ; Sekiguchi, Sadayoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5933-1ebf9c5baf6162366ef26f756c6c6fab0aa5fdb4f74c6599b97e185ce0723d623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Adolescent</topic><topic>Age</topic><topic>Age Factors</topic><topic>Agglutination</topic><topic>Agglutination Tests</topic><topic>AIDS/HIV</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Antigens, Viral - analysis</topic><topic>Biological and medical sciences</topic><topic>Blood donor</topic><topic>Blood Donors</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>Carrier State - microbiology</topic><topic>Enzyme immunoassay</topic><topic>Fluorescent Antibody Technique</topic><topic>Gag protein</topic><topic>Gelatin</topic><topic>HTLV-I Infections - microbiology</topic><topic>HTLV‐I seroscreening</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Immunofluorescence</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>p53 Protein</topic><topic>PAI</topic><topic>PA‐positive/IF‐negative</topic><topic>Serologic Tests</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Western blotting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kwon, Kil‐Won</creatorcontrib><creatorcontrib>Ikeda, Hisami</creatorcontrib><creatorcontrib>Yano, Misako</creatorcontrib><creatorcontrib>Sekiguchi, Sadayoshi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kwon, Kil‐Won</au><au>Ikeda, Hisami</au><au>Yano, Misako</au><au>Sekiguchi, Sadayoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the Human T‐Cell Leukemia Virus Type I Seropositivity of Blood Donors by the Particle Agglutination Inhibition Test</atitle><jtitle>Cancer science</jtitle><addtitle>Jpn J Cancer Res</addtitle><date>1989-09</date><risdate>1989</risdate><volume>80</volume><issue>9</issue><spage>833</spage><epage>839</epage><pages>833-839</pages><issn>0910-5050</issn><issn>1347-9032</issn><eissn>1349-7006</eissn><eissn>1876-4673</eissn><coden>GANNA2</coden><abstract>In the HTLV‐I seroscreening of blood donor sera by gelatin particle agglutination (PA), more than 50% (55.6%) of the PA‐positive sera were negative by immunofluorescence assay (IF). However, when donors were divided into age groups, there were increasing numbers of IF‐positive/PA‐positive donors with age. Among the PA‐positive donors in the 50–64 age group, 65.9% were IF‐positive compared to 16.0% in the 16–19 age group. The serological specificities of the IF‐negative/ PA‐positive specimens were tested by using a newly developed PA inhibition (PAD test. The HTLV‐I specificity of the PAI test was confirmed by the observation that agglutinations with anti‐HTLV‐I p19 and gp21 monoclonal antibodies as well as IF‐positive sera were specifically inhibited with HTLV‐I preparations or HTLV‐I‐positive cell extracts and not with HTLV‐I‐negative cell extracts. Sixty of the 104 specimens collected randomly from the IF‐negative/PA‐positive donors were PAI‐positive. The majority (80%) of such PAI‐positive sera showed more than two bands of HTLV‐I gag‐encoded polypeptide, p19, p24, p2S and p53 on Western blotting. Some of the PAI‐positive sera were also positive by enzyme immunoassay. These results indicate that at least some of the IF‐negative/ PA‐positive donors possess HTLV‐I‐specific antibody and may be potential HTLV‐I carriers who will become IF‐positive at a later age</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>2513300</pmid><doi>10.1111/j.1349-7006.1989.tb01723.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0910-5050 |
ispartof | Cancer science, 1989-09, Vol.80 (9), p.833-839 |
issn | 0910-5050 1347-9032 1349-7006 1876-4673 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5917853 |
source | Publicly Available Content Database; PubMed Central |
subjects | Adolescent Age Age Factors Agglutination Agglutination Tests AIDS/HIV Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antigens, Viral - analysis Biological and medical sciences Blood donor Blood Donors Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis Carrier State - microbiology Enzyme immunoassay Fluorescent Antibody Technique Gag protein Gelatin HTLV-I Infections - microbiology HTLV‐I seroscreening Humans Immunoenzyme Techniques Immunofluorescence Medical sciences Middle Aged Monoclonal antibodies p53 Protein PAI PA‐positive/IF‐negative Serologic Tests Transfusions. Complications. Transfusion reactions. Cell and gene therapy Western blotting |
title | Evaluation of the Human T‐Cell Leukemia Virus Type I Seropositivity of Blood Donors by the Particle Agglutination Inhibition Test |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-03-04T09%3A25%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20Human%20T%E2%80%90Cell%20Leukemia%20Virus%20Type%20I%20Seropositivity%20of%20Blood%20Donors%20by%20the%20Particle%20Agglutination%20Inhibition%20Test&rft.jtitle=Cancer%20science&rft.au=Kwon,%20Kil%E2%80%90Won&rft.date=1989-09&rft.volume=80&rft.issue=9&rft.spage=833&rft.epage=839&rft.pages=833-839&rft.issn=0910-5050&rft.eissn=1349-7006&rft.coden=GANNA2&rft_id=info:doi/10.1111/j.1349-7006.1989.tb01723.x&rft_dat=%3Cproquest_pubme%3E2400010414%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5933-1ebf9c5baf6162366ef26f756c6c6fab0aa5fdb4f74c6599b97e185ce0723d623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2400010414&rft_id=info:pmid/2513300&rfr_iscdi=true |